About
Attovia Therapeutics, Inc.
Attovia Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops biotherapeutics for immune-mediated diseases in the United States. The company provides ATTOBODY, a biparatopic biologics platform designed to deliver improved treatments.
The company’s products include ATTO-1310, a novel ATTOBODY-based Fc-fusion protein therapeutic that inhibits IL-31; developed for the treatment of chronic pruritic diseases such as CPUO, high-itch AD, cholestatic pruritus, and CKD-aP; ATTO-2306, an ATTOBODY-based, half-life-extended immunoglobulin G (IgG)-fusion protein therapeutic that inhibits IL-13 and IL-31; developed for the treatment of AD and other immune-mediated skin diseases, such as CSU and PN; and ATTO-1091, a trispecific ATTOBODY-based Fc-fusion protein therapeutic that inhibits TL1A, IL-23, and integrin a4ß7; developed for IBD a chronic immune-mediated condition characterized by persistent inflammation of the gastrointestinal tract, includes ulcerative colitis (UC) and croh
Attovia Therapeutics, Inc. Overview
Ticker, listing venue and issuer profile
Offer & Key Dates
Pricing terms and IPO milestones
Change from offer price to today
Live Market Snapshot
Real-time price; headline % change is vs first trade (listing price)
USD · NASDAQ:NASDAQ:ATTO
Valuation & Multiples
Key valuation ratios and metrics
Financial Health
Balance sheet strength and liquidity
Risk Metrics
Volatility versus the market
Financial Highlights
Historical financial performance
Historical Data
Market history and supplemental quote data
| Date | Open | High | Low | Close | Adj. Close | Change | Volume |
|---|---|---|---|---|---|---|---|
| 2026-08-27 | $19.66 | $21.50 | $19.10 | $21.46 | $21.46 | +1.80 | 137,300 |
| 2026-08-26 | $19.43 | $20.35 | $18.85 | $19.55 | $19.55 | +0.12 | 143,300 |
| 2026-08-25 | $20.83 | $21.96 | $19.11 | $19.31 | $19.31 | -1.52 | 189,300 |
| 2026-08-24 | $20.80 | $20.96 | $19.74 | $20.62 | $20.62 | -0.18 | 81,000 |
| 2026-08-21 | $20.21 | $21.01 | $19.70 | $20.80 | $20.80 | +0.59 | 362,200 |
| 2026-08-20 | $21.86 | $22.81 | $20.21 | $20.21 | $20.21 | -1.65 | 443,800 |
| 2026-08-19 | $23.35 | $24.32 | $21.02 | $22.14 | $22.14 | -1.21 | 364,300 |
| 2026-08-18 | $23.26 | $23.75 | $20.96 | $23.24 | $23.24 | -0.02 | 181,600 |
| 2026-08-17 | $19.85 | $22.71 | $19.85 | $22.71 | $22.71 | +2.86 | 149,500 |
| 2026-08-14 | $19.12 | $19.94 | $18.20 | $19.86 | $19.86 | +0.74 | 98,200 |
| 2026-08-13 | $18.06 | $19.36 | $17.97 | $19.18 | $19.18 | +1.12 | 406,500 |
| 2026-08-12 | $18.68 | $19.30 | $16.15 | $18.06 | $18.06 | -0.62 | 603,900 |
| 2026-08-11 | $19.84 | $20.50 | $18.65 | $18.65 | $18.65 | -1.19 | 475,600 |
| 2026-08-10 | $20.17 | $20.17 | $18.50 | $19.84 | $19.84 | -0.33 | 376,600 |
| 2026-08-07 | $20.11 | $20.94 | $18.64 | $20.17 | $20.17 | +0.06 | 237,900 |
| 2026-08-06 | $22.05 | $22.05 | $19.63 | $20.38 | $20.38 | -1.67 | 413,200 |
| 2026-08-05 | $21.00 | $22.79 | $20.21 | $21.90 | $21.90 | +0.90 | 4,907,300 |
SEC Filings
Official documents from SEC EDGAR
| Form | Filing Date | Document |
|---|---|---|
| 144 | Aug 28, 2026 | Filing |
| SCHEDULE 13G | Aug 12, 2026 | Filing |
| SCHEDULE 13D | Aug 11, 2026 | Filing |
| 4 | Aug 6, 2026 | Statement of changes in beneficial ownership of securities |
| 4 | Aug 6, 2026 | Statement of changes in beneficial ownership of securities |
| 8-K | Aug 6, 2026 | Current Report |
| S-8 | Aug 6, 2026 | Securities to be offered to employees in employee benefit plans |
| 424B4 | Aug 5, 2026 | Prospectus |
| EFFECT | Aug 4, 2026 | Notice of Effectiveness |
| 3 | Aug 4, 2026 | Initial statement of beneficial ownership of securities |
Company Info
Contact and headquarters details
Leadership
Key executives and officers
Tao Fu
Chief Executive Officer, President and Director
Zaneta Odrowaz, Ph.D.
Chief Business Officer, Treasurer, Secretary
Steven Chan
Chief Financial Officer
Petter Veiby
Chief Scientific Officer
Hubert Chen, M.D.
Chief Medical Officer
James Topper, M.D., Ph.D.
Chairman and Director
Mitchell Gold, M.D.
Director
Rebecca Luse.
Director
Aaron Royston, M.D.
Director
John W. Smither
Director
